Atara Biotherapeutics Inc reports results for the quarter ended in December - Earnings Summary

Atara Biotherapeutics

08/02/2023 22:02

* Atara Biotherapeutics Inc  ATRA.OQ  reported a quarterly
adjusted loss of 72 cents​​ per share for the quarter ended in
December. The mean expectation of ten analysts for the quarter
was for a loss of 51 cents per share.
    * Revenue fell 97.1% to $221.00 thousand from a year ago;
analysts
expected $39.67 million. 
    * Atara Biotherapeutics Inc's reported EPS for the quarter
was a
loss of 72 cents​.
    * The mean earnings estimate of analysts had risen by
about 18.8%
in the last three months.​ 
    * In the last 30 days there have been no negative revisions
of
earnings estimates 
    * Atara Biotherapeutics Inc shares had risen by 66.5% this
quarter.
    * The company reported a quarterly loss of $74.57 million.
    * Wall Street's median 12-month price target for Atara
Biotherapeutics Inc is $15.00 
    * The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is 6 "strong buy" or "buy," 2
"hold" and 2 "sell" or "strong sell." 

This summary was machine generated from Refinitiv data February
8 at 10:02 p.m.  ​All figures in US dollars unless otherwise
stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Dec. 31 2022      -0.51          -0.72          Missed
 Sep. 30 2022      -0.78          -0.82          Missed
 Jun. 30 2022      -0.93          -0.31          Beat
 Mar. 31 2022      -0.98          -0.87          Beat